A Comparison of the Safety and Comfort of AC-170
Information source: Aciex Therapeutics, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Normal Ocular Health
Intervention: AC-170 0.17% (Drug); AC-170 0.24% (Formulation 1) (Drug); AC-170 0.24% (Formulation 2) (Drug); Olopatadine hydrochloride 0.2% (Drug); Tears Naturale II (vehicle) (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Aciex Therapeutics, Inc.
Summary
The purpose of this study is to evaluate the safety and comfort of AC-170 compared to a
placebo.
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Primary outcome: Drop Comfort Score
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Able and willing to avoid the use of ocular medications or topical ocular
preparations within protocol specific time period.
Exclusion Criteria:
- Known contraindications or sensitivities to the study medication or its components.
- Any ocular condition that, in the opinion of the investigator, could affect the
subjects safety or trial parameters.
- Use of disallowed medications during the period indicated prior to the study
enrollment or during the study.
Locations and Contacts
Andover Eye Associates, Andover, Massachusetts 01810, United States
Additional Information
Starting date: December 2011
Last updated: June 23, 2015
|
